Market closed

GH Research/$GHRS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About GH Research

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Ticker

$GHRS
Trading on

Industry

Pharmaceuticals

Headquarters

Dublin, Ireland

Employees

50

GH Research Metrics

BasicAdvanced
$537M
-
-$0.75
0.94
-
$537M
0.94
$20.50
$6.00
258K
17.226
16.872
0.206
0.349
-70.08%
-15.15%
-19.58%
2.52
2.52
-10.643
9.47%
52.62%

What the Analysts think about GH Research

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for GH Research stock.

GH Research Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

GH Research Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GHRS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for GH Research stock?

GH Research (GHRS) has a market cap of $537M as of April 12, 2025.

What is the P/E ratio for GH Research stock?

The price to earnings (P/E) ratio for GH Research (GHRS) stock is 0 as of April 12, 2025.

Does GH Research stock pay dividends?

No, GH Research (GHRS) stock does not pay dividends to its shareholders as of April 12, 2025.

When is the next GH Research dividend payment date?

GH Research (GHRS) stock does not pay dividends to its shareholders.

What is the beta indicator for GH Research?

GH Research (GHRS) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.